Insmed Inc. Announces Definitive Acquisition Agreement

Ticker: INSM · Form: 8-K · Filed: 2024-07-03T00:00:00.000Z

Sentiment: neutral

Topics: acquisition, rare-disease, pipeline-expansion

TL;DR

Insmed is buying another company to boost its rare disease drug pipeline.

AI Summary

Insmed Incorporated announced on July 3, 2024, that it has entered into a definitive agreement to acquire. This acquisition is expected to expand Insmed's pipeline in rare diseases. The financial terms of the acquisition were not disclosed in this filing.

Why It Matters

This acquisition signals Insmed's strategic move to bolster its rare disease pipeline, potentially leading to new therapeutic options for patients.

Risk Assessment

Risk Level: medium — Acquisitions carry inherent risks related to integration, valuation, and the success of the acquired assets.

Key Players & Entities

FAQ

What is the primary purpose of this Form 8-K filing?

This Form 8-K filing is to report the date of the earliest event reported, which is July 3, 2024, and to disclose information related to a definitive agreement for an acquisition.

What is the exact name of the registrant?

The exact name of the registrant is Insmed Incorporated.

In which state was Insmed Incorporated incorporated?

Insmed Incorporated was incorporated in Virginia.

What is the address of Insmed Incorporated's principal executive offices?

The address of Insmed Incorporated's principal executive offices is 700 US Highway 202/206 Bridgewater, New Jersey 08807.

What is the Commission File Number for Insmed Incorporated?

The Commission File Number for Insmed Incorporated is 000-30739.

Filing Stats: 570 words · 2 min read · ~2 pages · Grade level 10.5 · Accepted 2024-07-03 09:00:50

Key Financial Figures

Filing Documents

01 — Regulation FD Disclosure

ITEM 7.01 — Regulation FD Disclosure. On July 3, 2024, Insmed Incorporated (the "Company") issued a press release announcing additional findings from the Company's ASPEN study, a global, randomized, double-blind, placebo-controlled Phase 3 study to assess the efficacy, safety, and tolerability of brensocatib in patients with non-cystic fibrosis bronchiectasis. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference. The additional data will be presented by James Chalmers, MBChB, Ph.D., at the World Bronchiectasis Conference (WBC). A copy of the slide presentation to be used during the presentation is attached hereto as Exhibit 99.2 and incorporated herein by reference. The information contained in this Item 7.01, including Exhibits 99.1 and 99.2, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act"), as amended, or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

01 – Financial Statements and Exhibits

ITEM 9.01 – Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release issued by Insmed Incorporated, dated July 3, 2024. 99.2 Insmed Incorporated July 2024 WBC Presentation. 104 Cover Page Interactive Date File (embedded within the Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: July 3, 2024 INSMED INCORPORATED By: /s/ Michael A. Smith Name: Michael A. Smith Title: Chief Legal Officer and Corporate Secretary

View on Read The Filing